Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara®)

Vaccine

Volumn 28, Issue 26, 2010, Pages 4288-4293

  Roukens, Anna H ^a   Vossen, Ann C ^a   Boland, Greet J ^b   Verduyn, Willem ^a   van Dissel, Jaap T ^a   Visser, Leo G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Hepatitis B vaccine; Imiquimod; Non response

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMIQUIMOD; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST;

ADULT; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; ARTICLE; CELL ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MALE; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN CELL; SKIN PIGMENTATION; VACCINATION;

ADMINISTRATION, CUTANEOUS; ADULT; AMINOQUINOLINES; ANTIBODY AFFINITY; ANTIBODY FORMATION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77952741268     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.029     Document Type: Article

References (42)

1. Dienstag J.L., Werner B.G., Polk B.F., Snydman D.R., Craven D.E., Platt R., et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 101 1 (1984) 34-40
2. Craven D.E., Awdeh Z.L., Kunches L.M., Yunis E.J., Dienstag J.L., Werner B.G., et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 105 1 (1986) 356-360
3. Struve J., Aronsson B., Frenning B., Forsgren M., and Weiland O. Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scan J Infect Dis 26 4 (1994) 468-470
4. Yu A.S., Cheung R.C., and Keeffe E.B. Hepatitis B vaccines. Infect Dis Clin North Am 20 1 (2006) 27-45
5. WHO Weekly epidemiological record; 2004. Available at: http://www.who.int/immunization/wer7928HepB_July04_position_paper.pdf [accessed 3.12.2008].
6. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303 15 (1980) 833-841
7. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315 4 (1986) 209-214
8. Walker M., Szmuness W., Stevens C.E., and Rubinstein P. Genetics of anti-HBs responsiveness. Transfusion 21 5 (1981) 601
9. Milich D.R., and Leroux-Roels G.G. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2 5 (2003) 248-257
10. Hadler S.C., and Margolis H.S. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 12 (1992) 282-308
11. Hollinger F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 3A 87 (1989) 36S-40S
12. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., and Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 270 24 (1993) 2935-2939
13. Cardell K., Akerlind B., Sällberg M., and Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 198 3 (2008) 299-304
14. Fabrizi F., Ganeshan S.V., Dixit V., and Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 24 5 (2006) 789-796
15. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 20 31-32 (2002) 3644-3649
16. Zoulek G., Lorbeer B., Jilg W., and Deinhardt Fl. Evaluation of a reduced dose of hepatitis B vaccine administered intradermally. Med Virol 14 1 (1984) 27-32
17. Miller K.D., Gibbs R.D., Mulligan M.M., Nutman T.B., and Francis D.P. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 2 8365-66 (1983) 1454-1456
18. Ronish R.H., Diniega B.M., Kelley P.W., Sjogren M.H., Arday D.R., Aronson N.E., et al. Immunogenicity achieved by the intradermal hepatitis B vaccination programme for US Army soldiers in Korea. Vaccine 9 5 (1991) 364-368
19. Ghabouli M.J., Sabouri A.H., Shoeibi N., Bajestan S.N., and Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur J Epidemiol 19 9 (2004) 871-875
20. Rahman F., Dahmen A., Herzog-Hauff S., Böcher W.O., Galle P.R., and Löhr H.F. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepathology 31 2 (2000) 521-527
21. Henderson E.A., Louie T.J., Ramotar K., Ledgerwood D., Hope K.M., and Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 21 4 (2000) 264-269
22. Chen W., and Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 4 (2005) CD000100
23. Sangare L., Manhart L., Zehrung D., and Wang C.C. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 27 (2009) 1777-1786
24. Micozkadioglu H., Zumrutdal A., Torun D., Sezer S., Ozdemir F.N., and Haberal M. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 29 3 (2007) 285-288
25. Fabrizi F., Dixit V., Magnini M., Elli A., and Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 24 3 (2006) 497-506
26. Verduyn W., Doxiades I.I., Anholts J.D., Drabbels J.J., Naipal A., D'Amaro J., et al. Biotinylated DRB sequence-specific oligonucleotides, comparison to serologic HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 37 1 (1993) 59-67
27. Helmberg W., Lanzer G., Zahn R., Weinmayr B., Wagner T., and Albert E. Virtual DNA analysis-a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 51 6 (1998) 587-592
28. Siegrist C.A., Pihlgren M., Tougne C., Efler S.M., Morris M.L., Al Adhami M.J., et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23 5 (2004) 615-622
29. Ghebrehewet S., Baxter D., Falconer M., and Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Hum Vaccin 4 (2008) 280-285
30. van Seters M., van Beurden M., ten Kate F.J., Beckmann I., Ewing P.C., Eijkemans M.J., et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Eng J Med 358 14 (2008) 1465-1473
31. Tyring S., Conant M., Marini M., Van Der Meijden W., and Washenik K. Imiquimod, an international update on therapeutic uses in dermatology. Int J Dermatol 41 11 (2002) 810-816
32. Burns Jr. R.P., Ferbel B., Tomai M., Miller R., and Gaspari A.A. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 94 1 (2000) 13-23
33. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114 1 (2000) 135-141
34. Thomsen L.L., Topley P., Daly M.G., Brett S.J., and Tite J.P. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22 13-14 (2004) 1799-1809
35. Zuber A.K., Bråve A., Engström G., Zuber B., Ljungberg K., Fredriksson M., et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 22 13-14 (2004) 1791-1798
36. Adams S., O'Neill D.W., Nonaka D., Hardin E., Chiriboga L., Siu K., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181 1 (2008) 776-784
37. Desombere I., Hauser P., Rossau R., Paradijs J., and Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 154 2 (1995) 520-529
38. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174 5 (2005) 2476-2480
39. Johnston D., and Bystryn J.C. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 24 11 (2006) 1958-1965
40. Smorlesi A., Papalini F., Orlando F., Donnini A., Re F., and Provinciali M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther 12 17 (2005) 1324-1332
41. Tyring S.K., Arany I., Stanley M.A., Tomai M.A., Miller R.L., Smith M.H., et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 178 2 (1998) 551-555
42. Nicolas J.F., and Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccin 7 8 (2008) 1201-1214